Morning Briefing
Summaries of health policy coverage from major news organizations
Microbicide Trials Network Stops Tenofovir Arm Of Study After Findings Show Drug Less Effective Than Anticipated
"The Microbicide Trials Network (MTN), which is funded by the U.S. National Institutes of Health, [on Wednesday] announced that it decided to stop one arm of a study involving more than 5,000 women in South Africa, Zimbabwe, and Uganda" after "an interim review of the ongoing trial by an independent monitoring board ... found that the drug tenofovir when used as pre-exposure prophylaxis (PrEP) had less effect in protecting women than anticipated," Science Magazine's "Science Insider" blog reports. "Although the board did not offer any specifics on how many women became infected on the drug versus placebo, they said continuing with the tenofovir arm was 'futile' as it would not yield meaningful results," the blog writes.
This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.
